Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cinepazet is a small molecule vasodilator and an ethyl ester derivative of cinepazic acid. It belongs to the class of alpha amino acid esters and features a piperazine ring with a trimethoxyphenyl group. Cinepazet acts primarily by inhibiting the influx of extracellular calcium into cells through slow calcium channels in the cell membrane. This mechanism leads to vasodilation and has been used for the treatment of angina pectoris and other cardiovascular conditions. The drug was marketed in France and Italy under the brand name Vascoril during the 1970s for cardiac therapy[9][10][7][5]. Its primary indication is as an antianginal agent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cinepazet.